胃癌治疗进展
早期可行内镜切除或微创手术,局部晚期以D2淋巴结清扫联合围手术期化疗(尤其奥沙利铂方案)为基础。免疫治疗联合化疗显著提高PD-L1阳性及MSI-H肿瘤的病理完全缓解率和总生存,CLDN18.2抗体与ADC药物革新治疗格局。
要点
- 早期胃癌内镜切除或微创手术可获与开腹手术相当的肿瘤学结局且恢复更快。
- 局部晚期胃癌根治手术为原发灶切除加D2淋巴结清扫,围手术期奥沙利铂化疗优于单纯手术。
- 免疫联合化疗在围手术期及晚期一线显著改善PD-L1阳性及MSI-H肿瘤的pCR率和OS。
核心结论
- 胃癌治疗正迈向以生物标志物驱动的个体化多学科模式,但获得性耐药与全球治疗可及性差异仍是重要挑战。
研究设计与样本
- 综述类文章,汇总胃癌内镜治疗、手术、围手术期化疗、免疫治疗、靶向治疗及新兴策略的进展。
主要发现
- 早期胃癌内镜切除或微创手术与开腹手术肿瘤学结局相当且恢复更快。
- 局部晚期胃癌围手术期奥沙利铂方案化疗较单纯手术显示生存获益。
- PD-1/PD-L1抑制剂联合化疗显著提高PD-L1阳性及MSI-H肿瘤的病理完全缓解率和总生存。
- Zolbetuximab为CLDN18.2阳性一线治疗建立新标准,T-DXd革新HER2阳性治疗格局。
关键数值与推荐
- D2淋巴结清扫定义为沿供胃血管两级淋巴结清扫。
- 围手术期化疗尤其奥沙利铂方案较单纯手术改善生存。
- 免疫联合化疗在PD-L1阳性及MSI-H肿瘤中显著改善pCR率和OS。
- Zolbetuximab为CLDN18.2阳性疾病一线新标准。
- T-DXd用于HER2阳性疾病。
临床怎么用
- 早期胃癌优先考虑内镜切除或微创手术。
- 局部晚期胃癌行原发灶切除加D2淋巴结清扫,并联合围手术期奥沙利铂化疗。
- 晚期一线根据PD-L1、MSI、CLDN18.2、HER2状态选择免疫、靶向或ADC治疗。
局限性
- 原文未报告具体研究设计、样本量、疗效数值及随访细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Gastric cancer remains a leading cause of cancer-related mortality worldwide, with nearly 1 million new cases diagnosed annually. Despite innovations in diagnosis, most patients still present at advanced stages, contributing to a poor prognosis. For early gastric cancer, endoscopic resection or minimally invasive surgery has become standard, offering comparable oncologic outcomes with faster recovery compared with open surgery. In locally advanced disease, resection of the primary lesion and D2 lymphadenectomy, defined as dissection of lymph nodes along two levels of blood vessels supplying the stomach, remains the cornerstone of curative surgery, whereas perioperative chemotherapy, particularly oxaliplatin-based regimens, has demonstrated improved survival benefits compared with surgery alone. The integration of immunotherapy into perioperative therapy for locally advanced disease and first-line palliative therapy for metastatic disease represents a paradigm shift, with programmed death 1/programmed death-ligand 1 inhibitors combined with chemotherapy significantly improving pathologic complete response rates and overall survival, especially in programmed death ligand 1-positive and microsatellite instability-high tumors. Targeted agents include claudin 18.2 antibody, with zolbetuximab establishing a new first-line standard for claudin 18.2-positive disease, and antibody-drug conjugates, such as trastuzumab deruxtecan for human epidermal growth factor receptor 2-positive disease, both of which have revolutionized treatment paradigms. Emerging strategies include dual immune checkpoint inhibition, bispecific antibodies, chimeric antigen receptor T-cell therapy, and fibroblast growth factor receptor 2b-targeting agents. Ultimately, the field is moving toward personalized, biomarker-driven approaches within multidisciplinary frameworks, although overcoming acquired resistance and addressing global disparities in therapeutic access remain important challenges.
引用
- Wang F, Wang ZX, Zhang YJ, et al. Advances in therapeutic approaches to gastric cancer. CA Cancer J Clin. 2026. PMID: 42751916. doi:10.3322/caac.70103
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。